The Green Journal

Axena Health Commends New Study Showing the Leva System’s Long-term Treatment Efficacy for Female Urinary Incontinence

Retrieved on: 
Tuesday, January 23, 2024
Women, Seniors, Physical Therapy, Health, FDA, Medical Devices, Health Technology, Consumer, Woman, Patient, Reproductive biology, Associate, MD, The Green Journal, Overactive bladder, Female, RCT, Harvard Medical School, Manager, FACS, PFMT, Urinary incontinence, University, Medicine, Quality of life, Risk, Incontinence, Food, Journal, FACOG, Storey, UI, Hospital, ACOG, Massachusetts General Hospital, American College, Birth control

Axena Health, Inc. (Axena Health), a medical device company focused on female pelvic health, announced today that leading pelvic health researchers have published a new study demonstrating the Leva® Pelvic Health System’s long-term treatment efficacy for female urinary incontinence (UI).

Key Points: 
  • Axena Health, Inc. (Axena Health), a medical device company focused on female pelvic health, announced today that leading pelvic health researchers have published a new study demonstrating the Leva® Pelvic Health System’s long-term treatment efficacy for female urinary incontinence (UI).
  • “Two years of data showing that UI symptom relief endures following eight weeks of guided-PFMT offers compelling evidence that women can access first-line, conservative treatment successfully.
  • “This newest published study offers powerful evidence that women can access first-line treatment successfully, and that this treatment has a lasting effect.
  • “Pelvic floor muscle training is globally recommended first-line treatment for urinary incontinence,” said Eileen Maus, CEO of Axena Health.

PFD Week Abstracts Show Leva’s Long-Term Treatment Value for Female Urinary Incontinence Plus New Data for Other Pelvic Floor Disorders

Retrieved on: 
Friday, October 6, 2023
Medical Devices, Health, Consumer, Hospitals, Women, Clinical Trials, The Green Journal, Nursing, Food, Female, Doctor of Philosophy, Abstract, Research, Prevalence, Urinary incontinence, PFMT, MD, Randomized controlled trial, Insurance, PFD, University, Massachusetts General Hospital, Hospital, Storey, Pelvic floor, Pelvic organ prolapse, FDA, Incontinence, FI, Harvard Medical School, POP, Vagina, Fecal incontinence, RCT, UI, Regulation of tobacco by the U.S. Food and Drug Administration, Woman, Richter, Quality of life, Birth control, Pharmaceutical industry, Dietary supplement, Gynaecology, Obstetrics

The Leva System is a non-drug, non-surgical treatment that helps women strengthen their pelvic floor at home, on their own schedule, by guiding correct and consistent pelvic floor muscle training (PFMT).

Key Points: 
  • The Leva System is a non-drug, non-surgical treatment that helps women strengthen their pelvic floor at home, on their own schedule, by guiding correct and consistent pelvic floor muscle training (PFMT).
  • The researchers presented their data in two abstracts during PFD Week 2023, the American Urogynecologic Society’s (AUGS) annual scientific meeting held in Portland, Ore. Oct. 4-6, 2023.
  • “We do, and it provides powerful validation of the Leva Pelvic Health System’s treatment value for women.
  • The research also showed that women with multiple pelvic floor disorders had more severe UI symptoms than women with UI only.

Axena Health delivers at-home treatment for chronic fecal incontinence in women

Retrieved on: 
Tuesday, June 20, 2023
Biotechnology, Medical Devices, Other Health, Health, Health Technology, Depression, Femtech, UI, European Journal of Obstetrics & Gynecology and Reproductive Biology, PFMT, The Green Journal, RCT, Quality of life, Incontinence, Woman, Guilt, Research, FACOG, Medicine, Leva, Associate, Reproductive biology, Harvard Medical School, Fecal incontinence, Feces, Shame, MD, Patient, Social stigma, Social isolation, Frustration, ABL, Chairperson, FACS, FDA, Massachusetts General Hospital, Pelvic floor dysfunction, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Female, Urinary incontinence, Birth control, Pharmaceutical industry, Obstetrics, Gynaecology

Axena Health, Inc. (Axena Health), a FemTech medical device company focused on scalable treatments for female pelvic health, introduced today the Leva®Pelvic Health System for the first-line treatment of chronic fecal incontinence (FI), also called accidental bowel leakage (ABL), in women.

Key Points: 
  • Axena Health, Inc. (Axena Health), a FemTech medical device company focused on scalable treatments for female pelvic health, introduced today the Leva®Pelvic Health System for the first-line treatment of chronic fecal incontinence (FI), also called accidental bowel leakage (ABL), in women.
  • In our study, we showed that the Leva System had the potential to improve fecal incontinence symptoms, which gives both clinicians and women an easy, practical way to access first-line treatment.
  • “Pelvic floor muscle training is a first-line treatment for both urinary and fecal incontinence,” said Samantha Pulliam, MD, FACOG, chief medical officer for Axena Health.
  • Thousands have used it to relieve symptoms of urinary incontinence, and we aspire to saying the same for women who experience fecal incontinence.

Axena Health Begins First-of-Its-Kind Global Study of Female Incontinence

Retrieved on: 
Wednesday, May 17, 2023
Health, Medical Devices, Consumer, Women, General Health, Pharmaceutical, Biotechnology, Well, AXA, PFMT, FI, Cigna, Fecal incontinence, Mother, MD, Disease, Society, GAVI, Johnson, Urinary incontinence, Bill & Melinda Gates Foundation, The Green Journal, Health equity, Ageing, Hope, Innovation, Research, UNICEF, Government, MS, Local government in Nepal, Organization, DPT, Equality, RCT, Johns Hopkins University Center for Communication Programs, BOSCH, Incontinence, Global Health, Ministry, Ministry of Health (Singapore), World Health Organization, United, MPH, Fistula, Family, UI, Woman, Leva, Female, Pharmaceutical industry, Nursing, Gynaecology, MBBS, Obstetrics

Axena Health, Inc. (Axena Health), a women’s health medical device company focused on scalable treatments for female pelvic health, announced today a large-scale study that will investigate the burdens of incontinence on women in low- and middle-income countries to support equitable access to treatment.

Key Points: 
  • Axena Health, Inc. (Axena Health), a women’s health medical device company focused on scalable treatments for female pelvic health, announced today a large-scale study that will investigate the burdens of incontinence on women in low- and middle-income countries to support equitable access to treatment.
  • “Urinary incontinence is a global health problem,” said Jessica McKinney, DScPT, MS, co-author of ‘ Implementing Physical Rehabilitation Services into Comprehensive Fistula and Maternity Care: A Training Guide for Health Workers ’, and Axena Health’s VP of Clinical Affairs and Global Health.
  • The burden of incontinence is gendered, and the costs borne by individuals and societies is multifactorial,” said Laura Keyser, DPT, MPH, co-author of the aforementioned Training Guide, and Director of Clinical Strategy and Global Health at Axena Health.
  • “Female incontinence is a significant unmet health need for millions of women worldwide, and we believe we’re uniquely able to help,” said Eileen Maus, CEO of Axena Health.

Axena Health Commends Obstetrics and Gynecology Publication Showing Leva® Pelvic Health System’s Long-Term Efficacy for Female Urinary Incontinence

Retrieved on: 
Wednesday, March 1, 2023
Health, Medical Devices, Consumer, Women, Clinical Trials, Research, Science, Medicine, Overactive bladder, American College, RCT, FI, Associate, The Green Journal, PFMT, Randomized controlled trial, Pelvic floor dysfunction, Massachusetts General Hospital, FDA, Regulation of tobacco by the U.S. Food and Drug Administration, ACOG, American College of Obstetricians and Gynecologists, AXA, Harvard Medical School, Kegel, Hospital, Urinary incontinence, MUI, Leva, Woman, Reproductive biology, Literature, SUI, Food, UI, PDT, Birth control, Pharmaceutical industry, Kegel exercise, Gynaecology, Obstetrics

The Leva Pelvic Health System (the Leva System) is a prescription digital therapeutic (PDT) that offers easy-to-use, at-home treatment for urinary and chronic fecal incontinence (FI) in women.

Key Points: 
  • The Leva Pelvic Health System (the Leva System) is a prescription digital therapeutic (PDT) that offers easy-to-use, at-home treatment for urinary and chronic fecal incontinence (FI) in women.
  • Of the 299 participants, women using the Leva System experienced durable, significantly greater improvement in UI symptoms compared with women who relied on Kegels alone.
  • The 2023 publication announced today shows that UI symptom improvement lasts, even without ongoing use of the Leva System.
  • “Urinary incontinence is common, but it should not be normal,” said Eileen Maus, CEO of Axena Health.